V. K. Somers, D. P. White, and R. Amin, Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing in collaboration with the National Heart, Lung, and Blood Institute National, Circulation, vol.118, pp.1080-1111, 2008.

L. F. Drager, L. A. Bortolotto, and M. C. Lorenzi, Early signs of atherosclerosis in obstructive sleep apnea, Am. J. Respir. Crit. Care Med, vol.172, pp.613-618, 2005.

E. Gautier-veyret, C. Arnaud, and M. Bäck, Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis, Eur. Respir. J, vol.42, pp.404-413, 2013.

C. Arnaud, L. Poulain, and P. Lévy, Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice, Atherosclerosis, vol.219, pp.425-431, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00786362

G. K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, N. Engl. J. Med, vol.352, pp.1685-1695, 2005.

B. Lefebvre, J. L. Pépin, and J. P. Baguet, Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea?, Eur. Respir. J, vol.32, pp.113-120, 2008.

F. Stanke-labesque, M. Bäck, and B. Lefebvre, Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia, J. Allergy Clin. Immunol, vol.124, pp.361-362, 2009.

D. Monneret, J. L. Pepin, and D. Godin-ribuot, Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima-media thickness in nonobese sleep apnea patients, Free Radic, Biol. Med, vol.48, pp.619-625, 2010.

F. Stanke-labesque, J. L. Pépin, and T. De-jouvencel, Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea, J. Lipid Res, vol.53, pp.1944-1951, 2012.

C. Arnaud, M. Dematteis, and J. L. Pepin, Obstructive sleep apnea, immunoinflammation, and atherosclerosis, Semin. Immunopathol, vol.31, pp.113-125, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00786340

P. Lévy, J. L. Pépin, and C. Arnaud, Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives, Eur. Respir. J, vol.32, pp.1082-1095, 2008.

M. Bäck, D. F. Ketelhuth, and S. , Matrix metalloproteinases in atherothrombosis, Prog. Cardiovasc. Dis, vol.52, pp.410-428, 2010.

J. Volná, D. Kemlink, and M. Kalousová, Biochemical oxidative stress-related markers in patients with obstructive sleep apnea, Med. Sci. Monit, vol.17, pp.491-497, 2011.

P. C. Calder, Mechanisms of action of (n-3) fatty acids, J. Nutr, vol.142, pp.592-599, 2012.

K. H. Weylandt, C. Y. Chiu, and B. Gomolka, Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation, Prostaglandins Other Lipid Mediat, vol.97, pp.73-82, 2012.

F. Stanke-labesque, P. Molière, and J. Bessard, Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers, Br. J. Nutr, vol.100, pp.829-833, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00267466

C. Schacky, PUFA in CVD: influence of cytokine polymorphism, Proc. Nutr. Soc, vol.66, issue.3, pp.166-170, 2007.

H. Poudyal, S. K. Panchal, and V. Diwan, Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action, Prog. Lipid Res, vol.50, pp.372-387, 2011.

J. Lefils, A. Géloën, and H. Vidal, Dietary DHA: time course of tissue uptake and effects on cytokine secretion in mice, Br. J. Nutr, vol.104, pp.1304-1312, 2010.

Z. Xu, N. Riediger, and S. Innis, Fish oil significantly alters fatty acid profiles in various lipid fractions but not atherogenesis in apo E-KO mice, Eur. J. Nutr, vol.46, pp.103-110, 2007.

A. Zampolli, A. Bysted, and T. Leth, Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models, Atherosclerosis, vol.184, pp.78-85, 2006.

H. H. Wang, T. M. Hung, and J. Wei, Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in ApoEknockout mice, Cardiovasc. Res, vol.61, pp.169-176, 2004.

M. Dematteis, D. Godin-ribuot, and C. Arnaud, Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease, ILAR J, vol.50, pp.262-281, 2009.

Y. Adan, K. Shibata, and W. Ni, Concentration of serum lipids and aortic lesion size in female and male apo E-deficient mice fed docosahexaenoic acid, Biosci. Biotechnol. Biochem, vol.63, pp.309-313, 1999.

T. A. Jacobson, S. B. Glickstein, and J. D. Rowe, Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review, J. Clin. Lipidol, vol.6, pp.5-18, 2012.

M. Matsumoto, M. Sata, and D. Fukuda, Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice, Atherosclerosis, vol.197, pp.524-533, 2008.

I. Mothe-satney, C. Filloux, and H. Amghar, Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice, Diabetes, vol.61, pp.2311-2319, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00726172

L. Poulain, A. Thomas, and J. Rieusset, Visceral white fat remodelling contributes to intermittent hypoxia-induced atherogenesis, Eur. Respir. J, vol.43, pp.513-522, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01859545

C. Reinke, S. Bevans-fonti, and L. F. Drager, Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes, J. Appl. Physiol, vol.111, pp.881-890, 2011.

F. Stanke-labesque, J. L. Pépin, and E. Gautier-veyret, Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis, Cardiovasc. Res, vol.101, pp.187-193, 2014.

P. C. Calder, The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability, Mol. Nutr. Food Res, vol.56, pp.1073-1080, 2012.

A. Dewell, F. F. Marvasti, and W. S. Harris, Low-and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome, J. Nutr, vol.141, pp.2166-2171, 2011.

H. M. Yusof, A. L. Cawood, and R. Ding, Limited impact of 2 g/day omega-3 fatty acid ethyl esters (Omacor s ) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy, Mar. Drugs, vol.11, pp.3569-3581, 2013.

M. Kuzuya, K. Nakamura, and T. Sasaki, Effect of MMP-2 deficiency on atherosclerotic lesion formation in ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol, vol.26, pp.1120-1125, 2006.

T. Young, M. Palta, and J. Dempsey, The occurrence of sleep-disordered breathing among middle-aged adults, N Engl J Med, vol.328, pp.1230-1235, 1993.

H. K. Yaggi, J. Concato, and W. N. Kernan, Obstructive sleep apnea as a risk factor for stroke and death, N Engl J Med, vol.353, pp.2034-2075, 2005.

V. K. Somers, D. P. White, and R. Amin, Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on, J Am Coll Cardiol, vol.52, pp.686-717, 2008.

J. Baguet, L. Hammer, and P. Lévy, The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence, Chest, vol.128, pp.3407-3419, 2005.

L. F. Drager, L. A. Bortolotto, and M. C. Lorenzi, Early signs of atherosclerosis in obstructive sleep apnea, Am J Respir Crit Care Med, vol.172, pp.613-621, 2005.

C. Arnaud, P. C. Beguin, and S. Lantuejoul, The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition, Am J Respir Crit Care Med, vol.184, pp.724-755, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00786346

C. Arnaud, L. Poulain, and P. Lévy, Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice, Atherosclerosis, vol.219, pp.425-456, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00786362

E. Gautier-veyret, C. Arnaud, M. Bäck, and J. Pépin, Intermittent hypoxiaactivated cyclooxygenase pathway: role in atherosclerosis, Eur Respir J, vol.42, pp.404-417, 2013.

L. Van-noolen, M. Bäck, and C. Arnaud, Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice, Prostaglandins Leukot Essent Fatty Acids, vol.91, pp.111-118, 2014.

G. K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, vol.352, pp.1685-95, 2005.

S. Ryan, C. T. Taylor, and W. T. Mcnicholas, Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome, Circulation, vol.112, pp.2660-2667, 2005.

C. Arnaud, M. Dematteis, and J. Pepin, Obstructive sleep apnea, immunoinflammation, and atherosclerosis, Semin Immunopathol, vol.31, pp.113-138, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00786340

G. Fang, D. Song, and X. Ye, Chronic intermittent hypoxia exposure induces atherosclerosis in ApoE knockout mice: role of NF-(B p50, Am J Pathol, vol.181, pp.1530-1539, 2012.

I. Tuleta, C. N. Franç-a, and D. Wenzel, Hypoxia-induced endothelial dysfunction in apolipoprotein E-deficient mice; effects of infliximab and L-glutathione, Atherosclerosis, vol.236, pp.400-410, 2014.

F. Stanke-labesque, M. Bäck, B. Lefebvre, R. Tamisier, J. Baguet et al., Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia, J Allergy Clin Immunol, vol.124, pp.1-2, 2009.

F. Stanke-labesque, J. Pépin, and T. De-jouvencel, Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea, J Lipid Res, vol.53, pp.1944-51, 2012.

S. Ryan, C. T. Taylor, and W. T. Mcnicholas, Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?, Postgrad Med J, vol.85, pp.693-701, 2009.

B. Lefebvre, J. Pépin, and J. Baguet, Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea?, Eur Respir J, vol.32, pp.113-133, 2008.

F. Stanke-labesque, J. Pépin, and E. Gautier-veyret, Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis, Cardiovasc Res, vol.101, pp.187-93, 2014.

J. Dogné, H. J. , and P. D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis, Trends Pharmacol Sci, vol.26, pp.639-683, 2005.

V. Capra, M. Bäck, and S. S. Barbieri, Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke, Med Res Rev, vol.33, pp.364-438, 2013.

S. Y. Tang, J. Monslow, and L. Todd, Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice, Circulation, vol.129, pp.1761-1770, 2014.

D. Praticò and J. Dogné, Vascular biology of eicosanoids and atherogenesis, Expert Rev Cardiovasc Ther, vol.7, pp.1079-89, 2009.

A. Ni?ankowska-j?drzejczyk, F. R. Almeida, and A. A. Lowe, Modulation of inflammatory and hemostatic markers in obstructive sleep apnea patients treated with mandibular advancement splints: a parallel, controlled trial, J Clin Sleep Med, vol.10, pp.255-62, 2014.

H. Kimura, M. Niijima, and Y. Abe, Compensatory excretion of prostacyclin and thromboxane metabolites in obstructive sleep apnea syndrome, Intern Med, vol.37, pp.127-160, 1998.

A. E. Beaudin, M. Pun, and C. Yang, Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea, J Am Heart Assoc, vol.3, p.875, 2014.

G. Davì, M. T. Guagnano, and G. Ciabattoni, Platelet activation in obese women, JAMA, vol.288, 2002.

F. Graziani, L. M. Biasucci, and P. Cialdella, Thromboxane production in morbidly obese subjects, Am J Cardiol, vol.107, pp.1656-61, 2011.

S. Basili, G. Pacini, and M. T. Guagnano, Insulin resistance as a determinant of platelet activation in obese women, J Am Coll Cardiol, vol.48, pp.2531-2539, 2006.

A. Canales, S. Bastida, and J. Librelottto, Platelet aggregation, eicosanoid production and thrombogenic ratio in individuals at high cardiovascular risk consuming meat enriched in walnut paste

, Br J Nutr, vol.102, pp.134-175, 2009.

P. Minuz, P. Patrignani, and S. Gaino, Determinants of platelet activation in human essential hypertension, Hypertension, vol.43, pp.64-70, 2004.

D. Praticò and J. Dogné, Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine, Circulation, vol.112, pp.1073-1082, 2005.

J. Krieger, D. Benzoni, and E. Sforza, Urinary excretion of prostanoids during sleep in obstructive sleep apnoea patients, Clin Exp Pharmacol Physiol, vol.18, pp.551-556, 1991.

W. Buczko, K. Kramkowski, and A. Mogielnicki, Are the endothelial mechanisms of ACE-Is already established?, Pharmacol Rep, vol.58, pp.126-157, 2006.

M. Nácher, R. Farré, and J. M. Montserrat, Biological consequences of oxygen desaturation and respiratory effort in an acute animal model of obstructive sleep apnea (OSA), Sleep Med, vol.10, pp.892-899, 2009.

R. Farré, M. Nácher, and A. Serrano-mollar, Rat model of chronic recurrent airway obstructions to study the sleep apnea syndrome, Sleep, vol.30, pp.930-933, 2007.

M. Dematteis, D. Godin-ribuot, and C. Arnaud, Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease, ILAR J, vol.50, pp.262-81, 2009.

R. C. Li, B. W. Row, and E. Gozal, Cyclooxygenase 2 and intermittent hypoxiainduced spatial deficits in the rat, Am J Respir Crit Care Med, vol.168, pp.469-75, 2003.

P. Klusonová, L. Reháková, and G. Borchert, Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart, Endocrinology, vol.150, pp.4270-4277, 2009.

T. Ohmori, Y. Yatomi, and T. Nonaka, Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients, J Thromb Haemost, vol.4, pp.1271-1279, 2006.

A. Alonso-fernández, F. García-río, and M. A. Arias, Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial, Thorax, vol.64, pp.581-587, 2009.

D. Monneret, J. Pepin, and D. Godin-ribuot, Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima-media thickness in nonobese sleep apnea patients, Free Radic Biol Med, vol.48, pp.619-644, 2010.

G. E. Carpagnano, S. A. Kharitonov, and O. Resta, 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy, Chest, vol.124, pp.1386-92, 2003.

K. Minoguchi, T. Yokoe, and A. Tanaka, Association between lipid peroxidation and inflammation in obstructive sleep apnoea, Eur Respir J, vol.28, pp.378-85, 2006.

A. Barceló, C. Miralles, and F. Barbé, Abnormal lipid peroxidation in patients with sleep apnoea, Eur Respir J, vol.16, pp.644-651, 2000.

J. F. Keaney, M. G. Larson, and R. S. Vasan, Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study, Arterioscler Thromb Vasc Biol, vol.23, pp.434-443, 2003.

B. A. Dennis, A. Ergul, and B. A. Gower, Oxidative stress and cardiovascular risk in overweight children in an exercise intervention program, Child Obes, vol.9, pp.15-21, 2013.

H. Urakawa, A. Katsuki, and Y. Sumida, Oxidative stress is associated with adiposity and insulin resistance in men, J Clin Endocrinol Metab, vol.88, pp.4673-4679, 2003.

S. Furukawa, T. Fujita, and M. Shimabukuro, Increased oxidative stress in obesity and its impact on metabolic syndrome, J Clin Invest, vol.114, pp.1752-61, 2004.

S. E. Craig, M. Kohler, and D. Nicoll, Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial, Thorax, vol.67, pp.1090-1096, 2012.

J. Pépin, R. Tamisier, and P. Lévy, Obstructive sleep apnoea and metabolic syndrome: put CPAP efficacy in a more realistic perspective, Thorax, vol.67, pp.1025-1032, 2012.

J. Pépin, R. Tamisier, and G. Barone-rochette, Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea, Am J Respir Crit Care Med, vol.182, pp.954-60, 2010.

M. Joyeux-faure, R. Tamisier, and J. Baguet, Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial, Mediators Inflamm, p.423120, 2014.

D. Praticò, C. Tillmann, and Z. B. Zhang, Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice, Proc Natl Acad Sci U S A, vol.98, pp.3358-63, 2001.

O. A. Belton, A. Duffy, and S. Toomey, Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis, Circulation, vol.108, pp.3017-3040, 2003.

T. Cyrus, S. Sung, and L. Zhao, Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice, Circulation, vol.106, pp.1282-1289, 2002.

A. J. Cayatte, Y. Du, and J. Oliver-krasinski, The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis, Arterioscler Thromb Vasc Biol, vol.20, pp.1724-1732, 2000.

N. F. Worth, C. L. Berry, A. C. Thomas, and J. H. Campbell, S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits, Atherosclerosis, vol.183, pp.65-73, 2005.

J. F. Viles-gonzalez, V. Fuster, and R. Corti, Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study, Eur Heart J, vol.26, pp.1557-61, 2005.

T. Cyrus, Y. Yao, and T. Ding, Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice, Blood, vol.109, pp.3291-3297, 2007.

C. Cherdon, S. Rolin, and J. Hanson, BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase, Prostaglandins Other Lipid Mediat, vol.94, pp.124-156, 2011.

T. Cyrus, Y. Yao, and T. Ding, A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice, Eur J Pharmacol, vol.561, pp.105-116, 2007.

D. Rott, J. Zhu, and M. S. Burnett, Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice, J Am Coll Cardiol, vol.41, pp.304-312, 2003.

M. E. Burleigh, V. R. Babaev, and J. A. Oates, Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice, Circulation, vol.105, pp.1816-1839, 2002.

F. Bea, E. Blessing, and B. J. Bennett, Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis, Cardiovasc Res, vol.60, pp.198-204, 2003.

G. A. Fitzgerald, Coxibs and cardiovascular disease, N Engl J Med, vol.351, pp.1709-1720, 2004.

A. A. Weber, K. C. Zimmermann, and J. Meyer-kirchrath, Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance, Lancet, vol.353, pp.498-503, 1999.

M. K. Halushka, Why are some individuals resistant to the cardioprotective effects of aspirin?: Could it be thromboxane A2?, Circulation, vol.105, pp.1620-1622, 2002.

K. M. Egan, M. Wang, and S. Fries, Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism, Circulation, vol.111, pp.334-376, 2005.

M. L. Bots, I. Ford, and S. M. Lloyd, Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial, Stroke, vol.45, pp.2348-53, 2014.

L. Belhassen, G. Pelle, and J. Dubois-rande, Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin, J Am Coll Cardiol, vol.41, pp.1198-204, 2003.

P. Lesault, L. Boyer, and G. Pelle, Daily administration of the TP receptor antagonist terutroban improved endothelial function in highcardiovascular-risk patients with atherosclerosis, Br J Clin Pharmacol, vol.71, pp.844-51, 2011.

H. R. Superko, A. R. Superko, and G. P. Lundberg, Omega-3 fatty acid blood levels clinical significance update, Curr Cardiovasc Risk Rep, vol.8, p.407, 2014.

D. Kromhout and J. De-goede, Update on cardiometabolic health effects of -3 fatty acids, Curr Opin Lipidol, vol.25, pp.85-90, 2014.

P. C. Calder, Mechanisms of action of (n-3) fatty acids, J Nutr, vol.142, pp.592-601, 2012.

P. C. Calder, Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance, Biochim Biophys Acta, 2014.

K. H. Weylandt, C. Chiu, and B. Gomolka, Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation, Prostaglandins Other Lipid Mediat, vol.97, pp.73-82, 2012.

F. Stanke-labesque, P. Molière, and J. Bessard, Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers, Br J Nutr, vol.100, pp.829-862, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00267466

P. C. Calder, The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability, Mol Nutr Food Res, vol.56, pp.1073-80, 2012.

P. Balková, J. Jezková, and M. Hlavácková, Dietary polyunsaturated fatty acids and adaptation to chronic hypoxia alter acyl composition of serum and heart lipids, Br J Nutr, vol.102, pp.1297-307, 2009.

J. Lefils, A. Géloën, and H. Vidal, Dietary DHA: time course of tissue uptake and effects on cytokine secretion in mice, Br J Nutr, vol.104, pp.1304-1316, 2010.

M. F. Chen, H. C. Hsu, and Y. T. Lee, Effects of fish oil supplementation on atherosclerosis in different regions of the aorta of rabbits with diet-induced hypercholesterolaemia, Clin Sci (Lond), vol.89, pp.497-504, 1995.

T. A. Mori, L. J. Beilin, and V. Burke, Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease, Arterioscler Thromb Vasc Biol, vol.17, pp.279-86, 1997.

C. Pirich, A. Gaszo, and S. Granegger, Effects of fish oil supplementation on platelet survival and ex vivo platelet function

V. K. Somers, D. P. White, R. Amin, W. T. Abraham, F. Costa et al., Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing, collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research, vol.118, pp.1080-111, 2008.

L. F. Drager, L. A. Bortolotto, M. C. Lorenzi, A. C. Figueiredo, E. M. Krieger et al., Early signs of atherosclerosis in obstructive sleep apnea, Am J Respir Crit Care Med, vol.172, issue.5, pp.613-621, 2005.

C. Arnaud, L. Poulain, P. Lévy, and M. Dematteis, Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice, Atherosclerosis, vol.219, issue.2, pp.425-456, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00786362

E. Gautier-veyret, C. Arnaud, M. Bäck, J. L. Pépin, M. H. Petri et al., Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis, Eur Respir J, vol.42, issue.2, pp.404-417, 2013.

L. Van-noolen, M. Bäck, C. Arnaud, A. Rey, M. H. Petri et al., Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia inducedatherosclerosis progression in apolipoprotein-E deficient mice, Prostaglandins Leukot Essent Fatty Acids, vol.91, issue.4, pp.111-118, 2014.

D. H. Chace, T. A. Kalas, and E. W. Naylor, The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism, Annu Rev Genomics Hum Genet, vol.3, pp.17-45, 2002.

S. E. Reuter and A. M. Evans, Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects, Clin Pharmacokinet, vol.51, issue.9, pp.553-72, 2012.

R. Friolet, H. Hoppeler, and S. Krähenbühl, Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions, J Clin Invest, vol.94, issue.4, pp.1490-1495, 1994.

E. Strand, E. R. Pedersen, G. F. Svingen, T. Olsen, B. Bjørndal et al., Serum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectoris, J Am Heart Assoc, vol.6, issue.2, 2017.

S. Rizza, M. Copetti, C. Rossi, M. A. Cianfarani, M. Zucchelli et al., Metabolomics signature improves the prediction of cardiovascular events in elderly subjects, Atherosclerosis, vol.232, issue.2, pp.260-264, 2014.

M. Guasch-ferré, Y. Zheng, M. Ruiz-canela, A. Hruby, M. A. Martínez-gonzález et al., Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions, Am J Clin Nutr, vol.103, issue.6, pp.1408-1424, 2016.

A. A. Shah, D. M. Craig, J. K. Sebek, C. Haynes, R. C. Stevens et al., Metabolic profiles predict adverse events after coronary artery bypass grafting, J Thorac Cardiovasc Surg, vol.143, issue.4, pp.873-881, 2012.

M. Miyata, A. Yoshihisa, H. Yamauchi, T. Owada, T. Sato et al., Impact of sleepdisordered breathing on myocardial damage and metabolism in patients with chronic heart failure, Heart Vessels, vol.30, issue.3, pp.318-342, 2015.

P. Lévy, M. Kohler, W. T. Mcnicholas, F. Barbé, R. D. Mcevoy et al., Obstructive sleep apnoea syndrome, Nat Rev Dis Primers, vol.1, p.15015, 2015.

R. Nadeem, M. Singh, M. Nida, S. Kwon, H. Sajid et al., Effect of CPAP treatment for obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis, J Clin Sleep Med, vol.10, issue.12, pp.1295-302, 2014.

E. Martínez-cerón, B. Barquiel, A. M. Bezos, R. Casitas, R. Galera et al., Effect of Continuous Positive Airway Pressure on Glycemic Control in Patients with Obstructive Sleep Apnea and Type 2 Diabetes. A Randomized Clinical Trial, Am J Respir Crit Care Med, vol.194, issue.4, pp.476-85, 2016.

K. Chin, T. Nakamura, K. Takahashi, K. Sumi, Y. Ogawa et al., Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients, Am J Med, vol.114, issue.5, pp.370-376, 2003.

I. Jullian-desayes, M. Joyeux-faure, R. Tamisier, S. Launois, A. L. Borel et al., Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: a systematic review from sham CPAP randomized controlled trials, Sleep Med Rev, vol.21, pp.23-38, 2015.

M. Dematteis, D. Godin-ribuot, C. Arnaud, C. Ribuot, F. Stanke-labesque et al., Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease, ILAR J, vol.50, issue.3, pp.262-81, 2009.

C. Minville, M. N. Hilleret, R. Tamisier, A. , J. Clement et al., Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea, Chest, vol.145, issue.3, pp.525-558, 2014.

R. B. Berry, R. Budhiraja, D. J. Gottlieb, D. Gozal, C. Iber et al., Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine, J Clin Sleep Med, vol.8, issue.5, pp.597-619, 2012.

R. Farré, L. Hernández, J. M. Montserrat, M. Rotger, E. Ballester et al., Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea, Lancet, vol.353, issue.9159, p.1154, 1999.

P. Rinaldo, T. M. Cowan, and D. Matern, Acylcarnitine profile analysis, Genet Med, vol.10, issue.2, pp.151-157, 2008.

S. M. Houten and R. J. Wanders, A general introduction to the biochemistry of mitochondrial fatty acid ?-oxidation, J Inherit Metab Dis, vol.33, issue.5, pp.469-77, 2010.

J. C. Jun, M. K. Shin, Q. Yao, S. Bevans-fonti, J. Poole et al., Acute hypoxia induces hypertriglyceridemia by decreasing plasma triglyceride clearance in mice, Am J Physiol Endocrinol Metab, vol.303, issue.3, p.377, 2012.

D. J. Eckert and A. Malhotra, Pathophysiology of adult obstructive sleep apnea, Proc Am Thorac Soc, vol.5, issue.2, pp.144-53, 2008.

, Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force, Sleep, vol.22, issue.5, pp.667-89, 1999.

O. Milleron, Risque cardiovasculaire et syndrome d'apnées du sommeil, MT Cardio, vol.1, issue.5, pp.397-406, 2005.

P. Lévy, M. Kohler, W. T. Mcnicholas, F. Barbé, R. D. Mcevoy et al., Obstructive sleep apnoea syndrome, Nat Rev Dis Primers, vol.1, p.15015, 2015.

W. T. Mcnicholas, M. R. Bonsigore, M. R. Bonsignore, and . Mcoeca, Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities, Eur Respir J, vol.29, issue.1, pp.156-78, 2007.

T. Kendzerska, A. S. Gershon, G. Hawker, R. S. Leung, and G. Tomlinson, Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade-long historical cohort study, PLoS Med, vol.11, issue.2, p.1001599, 2014.

N. S. Marshall, K. K. Wong, P. Y. Liu, S. R. Cullen, M. W. Knuiman et al., Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study, Sleep, vol.31, issue.8, pp.1079-85, 2008.

S. Javaheri, F. Barbe, F. Campos-rodriguez, J. A. Dempsey, R. Khayat et al., Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences, J Am Coll Cardiol, vol.69, issue.7, pp.841-58, 2017.

P. Lavie, P. Herer, and V. Hoffstein, Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study, BMJ, vol.320, issue.7233, pp.479-82, 2000.

C. M. Hoyos, L. F. Drager, and S. R. Patel, OSA and cardiometabolic risk: What's the bottom line?, Respirology, vol.22, issue.3, pp.420-429, 2017.

V. K. Somers, D. P. White, R. Amin, W. T. Abraham, F. Costa et al., Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing, collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research, vol.118, pp.1080-111, 2008.

F. Fatureto-borges, G. Lorenzi-filho, and L. F. Drager, Effectiveness of continuous positive airway pressure in lowering blood pressure in patients with obstructive sleep apnea: a critical review of the literature, Integr Blood Press Control, vol.9, pp.43-50, 2016.

Y. K. Loke, J. W. Brown, C. S. Kwok, A. Niruban, and P. K. Myint, Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis, Circ Cardiovasc Qual Outcomes, vol.5, issue.5, pp.720-728, 2012.

J. Baroin, Risque cardiovasculaire et syndrome d'apnées-hypopnées obstructives du sommeil. La lettre du cardiologue, vol.460, pp.10-17, 2012.

M. A. Martínez-garcía, J. J. Soler-cataluña, L. Ejarque-martínez, Y. Soriano, and P. Román-sánchez,

F. B. Illa, Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study, Am J Respir Crit Care Med, vol.180, issue.1, pp.36-41, 2009.

Y. Peker, J. Carlson, and J. Hedner, Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up, Eur Respir J, vol.28, issue.3, pp.596-602, 2006.

A. Cassar, T. I. Morgenthaler, R. J. Lennon, C. S. Rihal, and A. Lerman, Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention, J Am Coll Cardiol, vol.50, issue.14, pp.1310-1314, 2007.

I. H. Stevenson, H. Teichtahl, D. Cunnington, S. Ciavarella, I. Gordon et al., Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function, Eur Heart J, vol.29, issue.13, pp.1662-1671, 2008.

R. Mehra, K. Principe-rodriguez, H. L. Kirchner, K. P. Strohl, C. J. Nalliah et al., Sleep apnea in acute coronary syndrome: high prevalence but low impact on 6-month outcome, J Cardiovasc Electrophysiol, vol.7, issue.6, pp.521-529, 2006.

, Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study, Circulation, vol.122, issue.4, pp.352-60, 2010.

M. R. Cowie, H. Woehrle, K. Wegscheider, C. Angermann, M. P. Ortho et al.,

, Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure, N Engl J Med, vol.373, issue.12, pp.1095-105, 2015.

L. Lavie, Obstructive sleep apnoea syndrome--an oxidative stress disorder, Sleep Med Rev, vol.7, issue.1, pp.35-51, 2003.

L. Lavie, Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain, Sleep Med Rev, vol.20, pp.27-45, 2015.

D. Ben, M. Fabiani, M. Loffredo, L. Polimeni, L. Carnevale et al., Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment, BMC Pulm Med, vol.12, p.36, 2012.

V. Bisogni, M. F. Pengo, G. Maiolino, and G. P. Rossi, The sympathetic nervous system and catecholamines metabolism in obstructive sleep apnoea, J Thorac Dis, vol.8, issue.2, pp.243-54, 2016.

A. Shamsuzzaman, R. S. Amin, A. D. Calvin, D. Davison, and V. K. Somers, Severity of obstructive sleep apnea is associated with elevated plasma fibrinogen in otherwise healthy patients, Sleep Breath, vol.18, issue.4, pp.761-767, 2014.

C. Liak and M. Fitzpatrick, Coagulability in obstructive sleep apnea, Can Respir J, vol.18, issue.6, pp.338-386, 2011.

C. M. Hoyos, K. L. Melehan, P. Y. Liu, R. R. Grunstein, and C. L. Phillips, Does obstructive sleep apnea cause endothelial dysfunction? A critical review of the literature, Sleep Med Rev, vol.20, pp.15-26, 2015.

S. K. Namtvedt, J. Hisdal, A. Randby, S. Agewall, E. Stranden et al., Impaired endothelial function in persons with obstructive sleep apnoea: impact of obesity, Heart, vol.99, issue.1, pp.30-34, 2013.

M. S. Ip, H. F. Tse, B. Lam, K. W. Tsang, and W. K. Lam, Endothelial function in obstructive sleep apnea and response to treatment, Am J Respir Crit Care Med, vol.169, issue.3, pp.348-53, 2004.

M. Kohler, S. Craig, J. Pepperell, D. Nicoll, D. J. Bratton et al., CPAP improves endothelial function in patients with minimally symptomatic OSA: results from a subset study of the MOSAIC trial, Chest, vol.144, issue.3, pp.896-902, 2013.

C. L. Phillips, M. Butlin, K. K. Wong, and A. P. Avolio, Is obstructive sleep apnoea causally related to arterial stiffness? A critical review of the experimental evidence, Sleep Med Rev, vol.17, issue.1, pp.7-18, 2013.

A. M. Wons and M. Kohler, Established vascular effects of continuous positive airway pressure therapy in patients with obstructive sleep apnoea-an update, J Thorac Dis, vol.7, issue.5, pp.912-921, 2015.

X. Lin, G. Chen, J. Qi, X. Chen, J. Zhao et al., Effect of continuous positive airway pressure on arterial stiffness in patients with obstructive sleep apnea and hypertension: a meta-analysis, Eur Arch Otorhinolaryngol, vol.273, issue.12, pp.4081-4089, 2016.

L. F. Drager, L. A. Bortolotto, M. C. Lorenzi, A. C. Figueiredo, E. M. Krieger et al., Early signs of atherosclerosis in obstructive sleep apnea, Am J Respir Crit Care Med, vol.172, issue.5, pp.613-621, 2005.

J. P. Baguet, L. Hammer, P. Lévy, H. Pierre, S. Launois et al., The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence, Chest, vol.128, issue.5, pp.3407-3419, 2005.

L. F. Drager, L. A. Bortolotto, A. C. Figueiredo, E. M. Krieger, and G. F. Lorenzi, Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea, Am J Respir Crit Care Med, vol.176, issue.7, pp.706-718, 2007.

S. Ryan, C. T. Taylor, and W. T. Mcnicholas, Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?, Postgrad Med J, vol.85, pp.693-701, 1010.

K. Minoguchi, T. Tazaki, T. Yokoe, H. Minoguchi, Y. Watanabe et al., Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome, Chest, vol.126, issue.5, pp.1473-1482, 2004.

S. Ryan, C. T. Taylor, and W. T. Mcnicholas, Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome, Circulation, vol.112, issue.17, pp.2660-2667, 2005.

S. Ryan, C. T. Taylor, and W. T. Mcnicholas, Predictors of elevated nuclear factor-kappaBdependent genes in obstructive sleep apnea syndrome, Am J Respir Crit Care Med, vol.174, issue.7, pp.824-854, 2006.

M. Nácher, A. Serrano-mollar, R. Farré, J. Panés, J. Seguí et al., Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea, Respir Physiol Neurobiol, vol.155, issue.1, pp.93-99, 2007.

C. Arnaud, P. C. Beguin, S. Lantuejoul, J. L. Pepin, C. Guillermet et al., The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition, Am J Respir Crit Care Med, vol.184, issue.6, pp.724-755, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00786346

L. Dyugovskaya, P. Lavie, and L. Lavie, Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients, Am J Respir Crit Care Med, vol.165, issue.7, pp.934-943, 2002.

C. Arnaud, M. Dematteis, J. L. Pepin, J. P. Baguet, and P. Lévy, Obstructive sleep apnea, immunoinflammation, and atherosclerosis, Semin Immunopathol, vol.31, issue.1, pp.113-138, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00786340

B. Lefebvre, J. L. Pépin, J. P. Baguet, R. Tamisier, M. Roustit et al., Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea?, Eur Respir J, vol.32, issue.1, pp.113-133, 2008.

F. Stanke-labesque, M. Bäck, B. Lefebvre, R. Tamisier, J. P. Baguet et al., Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia, J Allergy Clin Immunol, vol.124, issue.2, pp.1-2, 2009.

D. Monneret, J. L. Pepin, D. Godin-ribuot, V. Ducros, J. P. Baguet et al., Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima-media thickness in nonobese sleep apnea patients, Free Radic Biol Med, vol.48, issue.4, pp.619-644, 2010.

C. T. Taylor, Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation, J Physiol, vol.586, issue.17, pp.4055-4064, 2008.

M. S. Ip, B. Lam, M. M. Ng, W. K. Lam, K. W. Tsang et al., Obstructive sleep apnea is independently associated with insulin resistance, Am J Respir Crit Care Med, vol.165, issue.5, pp.670-676, 2002.

L. F. Drager, L. Drager, V. Y. Polotsky, and L. Polotsky, Lipid metabolism: a new frontier in sleep apnea research, Am J Respir Crit Care Med, vol.184, issue.3, pp.288-90, 2011.

V. Savransky, A. Nanayakkara, J. Li, S. Bevans, P. L. Smith et al., Chronic intermittent hypoxia induces atherosclerosis, Am J Respir Crit Care Med, vol.175, issue.12, pp.1290-1297, 2007.

V. Savransky, J. Jun, J. Li, A. Nanayakkara, S. Fonti et al., Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase, Circ Res, vol.103, issue.10, pp.1173-80, 2008.

C. L. Phillips, B. J. Yee, N. S. Marshall, P. Y. Liu, D. R. Sullivan et al., Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomized, placebo-controlled crossover trial, Am J Respir Crit Care Med, vol.184, issue.3, pp.355-61, 2011.

C. Colette and L. Monnier, Acides gras : classification, fonction et équilibre entre les différentes familles. Médecine des maladies métaboliques, vol.5, pp.237-282, 2011.

H. Poudyal, S. K. Panchal, V. Diwan, and L. Brown, Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action, Prog Lipid Res, vol.50, issue.4, pp.372-87, 2011.

L. M. Arterburn, E. B. Hall, and H. Oken, Distribution, interconversion, and dose response of n-3 fatty acids in humans, Am J Clin Nutr, vol.83, issue.6, pp.1467-76, 2006.

P. C. Calder, Omega-3 fatty acids and inflammatory processes: from molecules to man, Biochem Soc Trans, vol.45, issue.5, pp.1105-1120, 2017.

G. Schmitz and J. Ecker, The opposing effects of n-3 and n-6 fatty acids, Prog Lipid Res, vol.47, issue.2, pp.147-55, 2008.

V. Capra, M. Bäck, S. S. Barbieri, M. Camera, E. Tremoli et al., Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke, Med Res Rev, vol.33, issue.2, pp.364-438, 2013.

P. C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance, Biochim Biophys Acta, vol.1851, issue.4, pp.469-84, 2015.

K. H. Weylandt, C. Y. Chiu, B. Gomolka, S. F. Waechter, and B. Wiedenmann, Omega-3 fatty acids and their lipid mediators: Towards an understanding of resolvin and protectin formation, Prostaglandins Other Lipid Mediat, vol.97, issue.3-4, pp.73-82, 2012.

C. N. Serhan, Pro-resolving lipid mediators are leads for resolution physiology, Nature, vol.510, issue.7503, pp.92-101, 2014.

H. Yanai, Y. Masui, H. Katsuyama, H. Adachi, A. Kawaguchi et al., An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids, J Clin Med Res, vol.10, issue.4, pp.281-290, 2018.

M. F. Burke, F. M. Burke, and D. E. Soffer, Review of Cardiometabolic Effects of Prescription Omega

, Fatty Acids, Curr Atheroscler Rep, vol.19, issue.12, p.60, 2017.

M. Bäck, Omega-3 fatty acids in atherosclerosis and coronary artery disease, Future Sci OA, vol.3, issue.4, p.236, 2017.

L. S. Sperling and J. R. Nelson, History and future of omega-3 fatty acids in cardiovascular disease, Curr Med Res Opin, vol.32, issue.2, pp.301-312, 2016.

H. O. Bang, J. Dyerberg, and N. Hjøorne, The composition of food consumed by Greenland Eskimos, Acta Med Scand, vol.200, issue.1-2, pp.69-73, 1976.

J. Dyerberg, H. O. Bang, and N. Hjorne, Fatty acid composition of the plasma lipids in Greenland Eskimos, Am J Clin Nutr, vol.28, issue.9, pp.958-66, 1975.

C. Von-schacky, Omega-3 fatty acids and cardiovascular disease, Curr Opin Clin Nutr Metab Care, vol.7, issue.2, pp.131-137, 2004.

P. C. Calder, n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored, Clin Sci (Lond), vol.107, issue.1, pp.1-11, 2004.

E. M. Balk, A. H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew et al., Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review, Atherosclerosis, vol.189, issue.1, pp.19-30, 2006.

M. A. Leslie, D. J. Cohen, D. M. Liddle, L. E. Robinson, and D. W. Ma, A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals, Lipids Health Dis, vol.14, p.53, 2015.

L. M. Neff, J. Culiner, S. Cunningham-rundles, C. Seidman, D. Meehan et al., Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults, J Nutr, vol.141, issue.2, pp.207-220, 2011.

P. E. Miller, M. Van-elswyk, and A. Dd, Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials, Am J Hypertens, vol.27, issue.7, pp.885-96, 2014.

D. Mozaffarian, A. Geelen, I. A. Brouwer, J. M. Geleijnse, P. L. Zock et al., Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials, Circulation, vol.112, issue.13, pp.1945-52, 2005.

C. Von-schacky, S. Fischer, and P. C. Weber, Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans, J Clin Invest, vol.76, issue.4, pp.1626-1657, 1985.

K. Li, T. Huang, J. Zheng, K. Wu, and D. Li, Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor ?: a meta-analysis, PLoS One, vol.9, issue.2, p.88103, 2014.

F. Thies, J. M. Garry, P. Yaqoob, K. Rerkasem, J. Williams et al., Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial, Lancet, vol.361, issue.9356, pp.477-85, 2003.

F. Stanke-labesque, J. L. Pépin, E. Gautier-veyret, P. Lévy, and M. Bäck, Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis, Cardiovasc Res, vol.101, issue.2, pp.187-93, 2014.

F. Stanke-labesque, P. Molière, J. Bessard, M. Laville, E. Véricel et al., Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers, Br J Nutr, vol.100, issue.4, pp.829-862, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00267466

A. Laguna-fernandez, A. Checa, M. Carracedo, G. Artiach, M. H. Petri et al.,

, ERV1/ChemR23 Signaling Protects from Atherosclerosis by Modifying oxLDL Uptake and Phagocytosis in Macrophages. Circulation, 2018.

P. Lévy, J. L. Pépin, C. Arnaud, R. Tamisier, J. C. Borel et al., Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives, Eur Respir J, vol.32, issue.4, pp.1082-95, 2008.

C. Arnaud, L. Poulain, P. Lévy, and M. Dematteis, Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice, Atherosclerosis, vol.219, issue.2, pp.425-456, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00786362

D. Caterina, R. Cybulsky, M. I. Clinton, S. K. Gimbrone, M. A. Libby et al., The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells, Arterioscler Thromb, vol.14, issue.11, pp.1829-1865, 1994.

B. Khalfoun, F. Thibault, H. Watier, P. Bardos, and Y. Lebranchu, Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6, Adv Exp Med Biol, vol.400, pp.589-97, 1997.

T. E. Novak, T. A. Babcock, D. H. Jho, W. S. Helton, and N. J. Espat, NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription, Am J Physiol Lung Cell Mol Physiol, vol.284, issue.1, pp.84-93, 2003.

G. Renier, E. Skamene, J. Desanctis, and D. Radzioch, Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Modulation of macrophage secretory activities, Arterioscler Thromb, vol.13, issue.10, pp.1515-1539, 1993.

P. Yaqoob and P. Calder, Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages, Cell Immunol, vol.163, issue.1, pp.120-128, 1995.

S. Sadeghi, F. A. Wallace, and P. C. Calder, Dietary lipids modify the cytokine response to bacterial lipopolysaccharide in mice, Immunology, vol.96, issue.3, pp.404-414, 1999.

S. Endres, R. Ghorbani, V. E. Kelley, K. Georgilis, G. Lonnemann et al., The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells, N Engl J Med, vol.320, issue.5, pp.265-71, 1989.

G. E. Caughey, E. Mantzioris, R. A. Gibson, L. G. Cleland, and M. J. James, The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil, Am J Clin Nutr, vol.63, issue.1, pp.116-138, 1996.

M. Bäck, D. F. Ketelhuth, and S. Agewall, Matrix metalloproteinases in atherothrombosis, Prog Cardiovasc Dis, vol.52, issue.5, pp.410-438, 2010.

S. K. Gunasinghe, J. Ikonomidis, and F. G. Spinale, Contributory role of matrix metalloproteinases in cardiovascular remodeling, Curr Drug Targets Cardiovasc Haematol Disord, vol.1, issue.2, pp.75-91, 2001.

J. Volná, D. Kemlink, M. Kalousová, J. Vávrová, V. Majerová et al., Biochemical oxidative stress-related markers in patients with obstructive sleep apnea, Med Sci Monit, vol.17, issue.9, pp.491-498, 2011.

L. P. Chuang, N. H. Chen, S. W. Lin, Y. L. Chang, I. J. Chao et al., Increased matrix metalloproteinases-9 after sleep in plasma and in monocytes of obstructive sleep apnea patients, Life Sci, vol.93, issue.5-6, pp.220-225, 2013.

A. L. Cawood, R. Ding, F. L. Napper, R. H. Young, J. A. Williams et al., Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability, Atherosclerosis, vol.212, issue.1, pp.252-261, 2010.

P. C. Calder, The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability, Mol Nutr Food Res, vol.56, issue.7, pp.1073-80, 2012.

J. D. Mcgarry and N. F. Brown, The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis, Eur J Biochem, vol.244, issue.1, pp.1-14, 1997.

P. De-lonlay, F. Djouadi, J. P. Bonnefont, J. M. Saudubray, and J. Bastin, Mitochondrial betaoxidation of fatty acids: an essential metabolic pathway of muscular function

, Arch Pediatr, vol.9, issue.2, pp.175-183, 2002.

S. M. Houten and R. J. Wanders, A general introduction to the biochemistry of mitochondrial fatty acid ?-oxidation, J Inherit Metab Dis, vol.33, issue.5, pp.469-77, 2010.

M. J. Bennett, Pathophysiology of fatty acid oxidation disorders, J Inherit Metab Dis, vol.33, issue.5, pp.533-540, 2010.

J. M. Saudubray, M. Baumgartner, and J. Walter, Inborn Metabolic Diseases -Diagnosis and Treatment

P. Rinaldo, T. M. Cowan, and D. Matern, Acylcarnitine profile analysis, Genet Med, vol.10, issue.2, pp.151-157, 2008.

S. J. Mihalik, B. H. Goodpaster, D. E. Kelley, D. H. Chace, J. Vockley et al., Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity, Obesity (Silver Spring), vol.18, issue.9, pp.1695-700, 2010.

E. Strand, E. R. Pedersen, G. F. Svingen, T. Olsen, B. Bjørndal et al., Serum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectoris, J Am Heart Assoc, vol.6, issue.2, 2017.

S. Rizza, M. Copetti, C. Rossi, M. A. Cianfarani, M. Zucchelli et al., Metabolomics signature improves the prediction of cardiovascular events in elderly subjects, Atherosclerosis, vol.232, issue.2, pp.260-264, 2014.

M. Guasch-ferré, Y. Zheng, M. Ruiz-canela, A. Hruby, M. A. Martínez-gonzález et al., Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions, Am J Clin Nutr, vol.103, issue.6, pp.1408-1424, 2016.

A. A. Shah, D. M. Craig, J. K. Sebek, C. Haynes, R. C. Stevens et al., Metabolic profiles predict adverse events after coronary artery bypass grafting, J Thorac Cardiovasc Surg, vol.143, issue.4, pp.873-881, 2012.

S. Kalim, C. B. Clish, J. Wenger, S. Elmariah, R. W. Yeh et al., A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients, J Am Heart Assoc, vol.2, issue.6, p.542, 2013.

M. Miyata, A. Yoshihisa, H. Yamauchi, T. Owada, T. Sato et al., Impact of sleepdisordered breathing on myocardial damage and metabolism in patients with chronic heart failure, Heart Vessels, vol.30, issue.3, pp.318-342, 2015.

C. E. Sullivan, F. G. Issa, M. Berthon-jones, and L. Eves, Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares, Lancet, vol.1, issue.8225, pp.862-867, 1981.

L. D. Sharples, C. , A. L. Glover, M. J. Bennett, M. S. Chadwick et al., Meta-analysis of randomised controlled trials of oral mandibular advancement devices and continuous positive airway pressure for obstructive sleep apnoea-hypopnoea, Sleep Med Rev, vol.27, pp.108-132, 2016.

J. L. Pépin, J. Krieger, D. Rodenstein, A. Cornette, E. Sforza et al., Effective compliance during the first 3 months of continuous positive airway pressure. A European prospective study of 121 patients, Am J Respir Crit Care Med, vol.160, issue.4, pp.1124-1133, 1999.

J. L. Pépin, R. Tamisier, and P. Lévy, Obstructive sleep apnoea and metabolic syndrome: put CPAP efficacy in a more realistic perspective, Thorax, vol.67, issue.12, pp.1025-1032, 2012.

D. P. White, Pharmacologic Approaches to the Treatment of Obstructive Sleep Apnea, Sleep Med Clin, vol.11, issue.2, pp.203-215, 2016.

E. Gautier-veyret, J. L. Pépin, and F. Stanke-labesque, Which place of pharmacological approaches beyond continuous positive airway pressure to treat vascular disease related to obstructive sleep apnea? Pharmacol Ther, 2017.

F. Stanke-labesque, J. L. Pépin, T. De-jouvencel, C. Arnaud, J. P. Baguet et al.,

, Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea, J Lipid Res, vol.53, issue.9, pp.1944-51, 2012.

E. Gautier-veyret, C. Arnaud, M. Bäck, J. L. Pépin, M. H. Petri et al., Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis, Eur Respir J, vol.42, issue.2, pp.404-417, 2013.

M. Dematteis, D. Godin-ribuot, C. Arnaud, C. Ribuot, F. Stanke-labesque et al., Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease, ILAR J, vol.50, issue.3, pp.262-81, 2009.

R. A. Rockerbie, R. D. Dobson, and J. Frohlich, Gas-chromatographic analysis of patterns of fatty acids of cholesteryl esters and phosphatidylcholine, Clin Chem, vol.25, issue.8, pp.1411-1415, 1979.

L. D. Metcalfe and A. A. Schmitz, The Rapid Preparation of Fatty Acid Esters for Gas Chromatographic Analysis, Analytical Chemitry, vol.33, issue.3, pp.363-64, 1961.

D. Cheillan, S. Cognat, C. Vianey-saban, M. I. Dorche, and C. , Application of tandem mass spectrometry to neonatal screening of inherited metabolic diseases: focus on present developments

, Ann Biol Clin (Paris), vol.62, issue.3, pp.269-77, 2004.

A. Elagizi, C. J. Lavie, K. Marshall, J. J. Dinicolantonio, J. H. O'keefe et al., , p.3

, Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review, Prog Cardiovasc Dis, 2018.

D. Praticò, C. Tillmann, Z. B. Zhang, H. Li, and G. A. Fitzgerald, Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice, Proc Natl Acad Sci, vol.98, issue.6, pp.3358-63, 2001.

O. A. Belton, A. Duffy, S. Toomey, and D. J. Fitzgerald, Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis, Circulation, vol.108, issue.24, pp.3017-3040, 2003.

T. Cyrus, S. Sung, L. Zhao, C. D. Funk, S. Tang et al., Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice, Circulation, vol.106, issue.10, pp.1282-1289, 2002.

M. F. Chen, H. C. Hsu, and Y. T. Lee, Effects of fish oil supplementation on atherosclerosis in different regions of the aorta of rabbits with diet-induced hypercholesterolaemia, Clin Sci (Lond), vol.89, issue.5, pp.497-504, 1995.

N. F. Worth, C. L. Berry, A. C. Thomas, and J. H. Campbell, S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits, Atherosclerosis, vol.183, issue.1, pp.65-73, 2005.

T. Cyrus, Y. Yao, T. Ding, J. M. Dogné, and D. Praticò, A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice, Eur J Pharmacol, vol.561, issue.1-3, pp.105-116, 2007.

C. Cherdon, S. Rolin, J. Hanson, A. Ooms, L. De-leval et al., BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase, Prostaglandins Other Lipid Mediat, vol.94, issue.3-4, pp.124-156, 2011.

P. F. Lesault, L. Boyer, G. Pelle, A. Covali-noroc, D. Rideau et al., Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascularrisk patients with atherosclerosis, Br J Clin Pharmacol, vol.71, issue.6, pp.844-51, 2011.

L. Van-noolen, M. Bäck, C. Arnaud, A. Rey, M. H. Petri et al., Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia inducedatherosclerosis progression in apolipoprotein-E deficient mice, Prostaglandins Leukot Essent Fatty Acids, vol.91, issue.4, pp.111-118, 2014.

J. B. Ladesich, J. V. Pottala, A. Romaker, and W. S. Harris, Membrane level of omega-3 docosahexaenoic acid is associated with severity of obstructive sleep apnea, J Clin Sleep Med, 2011.

K. Nakabayashi, K. Jujo, K. Saito, T. Oka, and N. Hagiwara, Evaluation of the association between sleep apnea and polyunsaturated fatty acids profiles in patients after percutaneous coronary intervention, Heart Vessels, vol.32, issue.11, pp.1296-303, 2017.

J. Tittus, M. T. Huber, K. Storck, A. Köhler, J. M. Köhler et al., Omega-3 Index and Obstructive Sleep Apnea: A Cross-Sectional Study, J Clin Sleep Med, vol.13, issue.10, pp.1131-1137, 2017.

F. A. Scorza, E. A. Cavalheiro, C. A. Scorza, J. C. Galduróz, S. Tufik et al., Sleep Apnea and Inflammation -Getting a Good Night's Sleep with Omega-3 Supplementation, Front Neurol, vol.4, p.193, 2013.

M. R. Alzoubi, A. Al-domi, and H. , Could omega-3 fatty acids a therapeutic treatment of the immune-metabolic consequence of intermittent hypoxia in obstructive sleep apnea?, Diabetes Metab Syndr, vol.11, issue.4, pp.297-304, 2017.

Z. Xu, N. Riediger, S. Innis, and M. H. Moghadasian, Fish oil significantly alters fatty acid profiles in various lipid fractions but not atherogenesis in apo E-KO mice, Eur J Nutr, vol.46, issue.2, pp.103-113, 2007.

A. Zampolli, A. Bysted, T. Leth, A. Mortensen, D. Caterina et al., Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models, Atherosclerosis, vol.184, issue.1, pp.78-85, 2006.

H. H. Wang, T. M. Hung, J. Wei, and A. N. Chiang, Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoE-knockout mice, Cardiovasc Res, vol.61, issue.1, pp.169-76, 2004.

R. Sun, X. Wang, Y. Liu, and M. Xia, Dietary supplementation with fish oil alters the expression levels of proteins governing mitochondrial dynamics and prevents high-fat diet-induced endothelial dysfunction, Br J Nutr, vol.112, issue.2, pp.145-53, 2014.

L. Liu, Q. Hu, H. Wu, Y. Xue, L. Cai et al., Protective role of n6/n3 PUFA supplementation with varying DHA/EPA ratios against atherosclerosis in mice, J Nutr Biochem, vol.32, pp.171-80, 2016.

Q. Wei, Y. Bian, F. Yu, Q. Zhang, G. Zhang et al., Chronic intermittent hypoxia induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model, J Biomed Res, vol.30, issue.6, pp.490-495, 2016.

E. Gautier-veyret, L. Van-noolen, P. Lévy, J. L. Pepin, and F. Stanke-labesque, Could the thromboxane A2 pathway be a therapeutic target for the treatment of obstructive sleep apneainduced atherosclerosis?, Prostaglandins Other Lipid Mediat, vol.121, pp.97-104, 2015.

C. S. Mccoin, T. A. Knotts, and S. H. Adams, Acylcarnitines--old actors auditioning for new roles in metabolic physiology, Nat Rev Endocrinol, vol.11, issue.10, pp.617-642, 2015.

W. G. Hunter, J. P. Kelly, R. W. Mcgarrah, M. G. Khouri, D. Craig et al., Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure, J Am Heart Assoc, vol.5, issue.8, 2016.

M. M. Sayed-ahmed, M. M. Khattab, M. Z. Gad, and N. Mostafa, L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits, Pharmacol Res, vol.44, issue.3, pp.235-277, 2001.

L. G. Spagnoli, A. Orlandi, B. Marino, A. Mauriello, C. De-angelis et al., Propionyl-Lcarnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits, Atherosclerosis, vol.114, issue.1, pp.29-44, 1995.

R. A. Koeth, Z. Wang, B. S. Levison, J. A. Buffa, E. Org et al., Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis, Nat Med, vol.19, issue.5, pp.576-85, 2013.

A. M. Johri, D. K. Heyland, M. F. Hétu, B. Crawford, and J. D. Spence, Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies, Nutr Metab Cardiovasc Dis, vol.24, issue.8, pp.808-822, 2014.

H. C. Blair, J. Sepulveda, and D. J. Papachristou, Nature and nurture in atherosclerosis: The roles of acylcarnitine and cell membrane-fatty acid intermediates, Vascul Pharmacol, vol.78, pp.17-23, 2016.

R. Vilskersts, J. Kuka, E. Liepinsh, M. Makrecka-kuka, K. Volska et al., Methyl-?-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis, Vascul Pharmacol, vol.72, pp.101-108, 2015.

J. M. Rutkowsky, T. A. Knotts, K. D. Ono-moore, C. S. Mccoin, S. Huang et al., Acylcarnitines activate proinflammatory signaling pathways, Am J Physiol Endocrinol Metab, vol.306, issue.12, pp.1378-87, 2014.

K. H. Jackson and W. S. Harris, Blood Fatty Acid Profiles: New Biomarkers for Cardiometabolic Disease Risk, Curr Atheroscler Rep, vol.20, issue.5, p.22, 2018.

S. Elmariah, L. A. Farrell, D. Furman, B. R. Lindman, X. Shi et al., Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement, JAMA Cardiol, vol.3, issue.3, pp.242-248, 2018.